Kiniksa Pharmaceuticals Shifts Strategic Focus with Key Agreement Terminations and 2024 Financial Results
Kiniksa Pharmaceuticals International plc (NASDAQ: KNSA) announced several significant developments in its SEC Form 8-K filing dated February 21, 2025, including the termination of a long‐standing license agreement and the release of its fourth quarter and full year 2024 financial results. On February 21, 2025, a wholly owned subsidiary of Kiniksa notified MedImmune Limited of […]
Kiniksa Pharmaceuticals International plc (NASDAQ: KNSA) announced several significant developments in its SEC Form 8-K filing dated February 21, 2025, including the termination of a long‐standing license agreement and the release of its fourth quarter and full year 2024 financial results. On February 21, 2025, a wholly owned subsidiary of Kiniksa notified MedImmune Limited of […]
